Company Description
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.
The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases.
Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 2015 |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Corey Fishman |
Contact Details
Address: 3 Dublin Landings, North Wall Quay Dublin, D01 C4E0 Ireland | |
| Phone | 353 1 903 8354 |
| Website | iterumtx.com |
Stock Details
| Ticker Symbol | ITRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659323 |
| CUSIP Number | G6333L101 |
| ISIN Number | IE000TTOOBX0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Corey N. Fishman | President, Chief Executive Officer and Director |
| Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor and Director |
| Tom Loughman Ph.D. | Senior Vice President of Technical Operations |
| Kevin Dalton | Senior Director of Legal Affairs and Company Secretary |
| Dr. Steven I. Aronin M.D. | Senior Vice President and Head of Clinical Development |
| Christine R. Coyne M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2026 | 8-K | Current Report |
| Feb 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 26, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 2, 2026 | DEF 14A | Other definitive proxy statements |
| Dec 23, 2025 | PRE 14A | Other preliminary proxy statements |
| Dec 12, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | 8-K | Current Report |
| Oct 16, 2025 | 8-K | Current Report |
| Oct 16, 2025 | 424B5 | Filing |